EXEL
Exelixis, Inc.
EXEL's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over EXEL overall, supported by stronger modeled upside and lower modeled downside.
EXEL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
EXEL's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
EXEL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 18x | $60.50 | -13% |
| Forward | 18x | $69.84 | — |
| Current | 21x | $69.84 | — |
| Fair | 24x | $79.95 | +14% |
| Expensive | 44x | $146 | +109% |
Historical ranges are pointers, not guarantees.
EXEL has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
EXEL Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for EXEL, with profitability improving. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
EXEL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.82 | +14% |
| Q3 2026 | $3.35 | +42% |
| Q2 2026 | $3.19 | +54% |
| Q1 2026 | $3.02 | +38% |
| Q4 2025 | $2.78 | +58% |
| Q3 2025 | $2.36 | +50% |
| Q2 2025 | $2.07 | +77% |
| Q1 2025 | $2.19 | +237% |
| Q4 2024 | $1.76 | +171% |
EXEL's earnings per share have climbed steadily: $3.35 over the past year, up 42% from the year before, and higher year over year for 12 quarters in a row.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over EXEL on earnings, with stronger typical year-over-year growth.
EXEL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $658.7M | +10% |
| Q2 2026 | $628.7M | +11% |
| Q1 2026 | $610.8M | +10% |
| Q4 2025 | $598.7M | +5.6% |
| Q3 2025 | $597.8M | +11% |
| Q2 2025 | $568.3M | -11% |
| Q1 2025 | $555.4M | +31% |
| Q4 2024 | $566.8M | +18% |
EXEL's revenue has grown year over year for five quarters in a row: $659M last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 41% | +1.2 points |
| Q2 2026 | 40% | +1.9 points |
| Q1 2026 | 41% | +7.5 points |
| Q4 2025 | 39% | +11 points |
| Q3 2025 | 40% | +14 points |
| Q2 2025 | 38% | -5.7 points |
| Q1 2025 | 34% | +27 points |
| Q4 2024 | 29% | +12 points |
EXEL has the edge over LLY on profitability, with a higher operating margin.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over EXEL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
EXEL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $277.5M | -3.9% |
| Q2 2026 | $300.9M | +552% |
| Q1 2026 | $250.3M | +20% |
| Q4 2025 | $332.4M | +41% |
| Q3 2025 | $288.8M | +9.8% |
| Q2 2025 | $46.2M | -59% |
| Q1 2025 | $208.5M | +253% |
| Q4 2024 | $236.3M | +$238.9M |
EXEL generated $1.2B in free cash flow over the past year, up 49% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
EXEL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.5% | -3.9M shares |
| 1 year | -8.2% | -22.8M shares |
| 3 years | -20% | -63.5M shares |
| 5 years | -21% | -66.3M shares |
| Available history | -19% | -59.3M shares |
EXEL has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $250M |
| Q2 2026 | $323M |
| Q1 2026 | $430.4M |
| Q4 2025 | $257.6M |
| Q3 2025 | $104M |
| Q2 2025 | $301.9M |
| Q1 2025 | $283.9M |
| Q4 2024 | $190.4M |
EXEL spent $1.3B buying back its own shares over the past year, up 43% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
EXEL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.2x | Net Cash |
| Q4 2025 | -0.5x | Net Cash |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | -0.2x | Net Cash |
| Q4 2024 | -0.3x | Net Cash |
EXEL has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
EXEL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 78.5 | Overbought |
| Stochastic | 84.7 | Overbought |
EXEL's weekly RSI is 79 (overbought) and its Stochastic is 85 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
EXEL PE vs Healthcare Sector
| Metric | EXEL | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 19% below |
| PE % | 36 | 29 | 7 pts above |
EXEL has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
EXEL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $64.0 | 9.1% above |
| 20 week MA | $58.8 | 19% above |
| 50 week MA | $50.9 | 37% above |
| 100 week MA | $44.8 | 56% above |
| 200 week MA | $33.7 | 107% above |
EXEL is in an uptrend: it's above all five of its weekly moving averages, and 107% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
EXEL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.1 | $20.7 | +14% |
| 2021 | $20.7 | $19.3 | -6.9% |
| 2022 | $19.3 | $15.8 | -18% |
| 2023 | $15.8 | $24.0 | +52% |
| 2024 | $24.0 | $33.8 | +41% |
| 2025 | $33.8 | $46.2 | +37% |
| 2026 YTD | $46.2 | $69.8 | +51% |
EXEL has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.